Skip to Content

Notice

Bulk Manufacturer of Controlled Substances Application: American Radiolabeled Chemicals

Document Details

Information about this document as published in the Federal Register.

Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble

ACTION:

Notice of application.

DATES:

Registered bulk manufacturers of the affected basic classes, and applicants therefore, may file written comments on or objections to the issuance of the proposed registration in accordance with 21 CFR 1301.33(a) on or before July 18, 2017.

ADDRESSES:

Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DRW, 8701 Morrissette Drive, Springfield, Virginia 22152.

End Preamble Start Supplemental Information

SUPPLEMENTARY INFORMATION:

The Attorney General has delegated his authority under the Controlled Substances Act to the Administrator of the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority to exercise all necessary functions with respect to the promulgation and implementation of 21 CFR part 1301, incident to the registration of manufacturers, distributors, dispensers, importers, and exporters of controlled substances (other than final orders in connection with suspension, denial, or revocation of registration) has been redelegated to the Assistant Administrator of the DEA Diversion Control Division (“Assistant Administrator”) pursuant to section 7 of 28 CFR part 0, appendix to subpart R.Start Printed Page 23071

In accordance with 21 CFR 1301.33(a), this is notice that on March 7, 2017, American Radiolabeled Chemicals, Inc., 101 Arc Drive, Saint Louis, Missouri 63146 applied to be registered as a bulk manufacturer of the following basic classes of controlled substances:

Controlled substanceDrug codeSchedule
Gamma Hydroxybutyric Acid2010I
Ibogaine7260I
Lysergic acid diethylamide7315I
Tetrahydrocannabinols7370I
Dimethyltryptamine7435I
1-[1-(2-Thienyl)cyclohexyl]piperidine7470I
Dihydromorphine9145I
Heroin9200I
Normorphine9313I
Amphetamine1100II
Methamphetamine1105II
Amobarbital2125II
Phencyclidine7471II
Phenylacetone8501II
Cocaine9041II
Codeine9050II
Dihydrocodeine9120II
Oxycodone9143II
Hydromorphone9150II
Ecgonine9180II
Hydrocodone9193II
Meperidine9230II
Metazocine9240II
Methadone9250II
Dextropropoxyphene, bulk (non-dosage forms)9273II
Morphine9300II
Oripavine9330II
Thebaine9333II
Oxymorphone9652II
Phenazocine9715II
Carfentanil9743II
Fentanyl9801II

The company plans to manufacture small quantities of the listed controlled substances as radiolabeled compounds for biochemical research.

Start Signature

Dated: May 15, 2017.

Louis J. Milione,

Assistant Administrator.

End Signature End Supplemental Information

[FR Doc. 2017-10240 Filed 5-18-17; 8:45 am]

BILLING CODE P